World Allergy Organization Journal最新文献

{"title":"Longitudinal multi-trajectory phenotypes of severe eosinophilic asthma on type 2 biologics treatment","authors":"Duong Duc Pham, MD, PhD ,&nbsp;Ji-Hyang Lee, MD, PhD ,&nbsp;Hyouk-Soo Kwon, MD, PhD ,&nbsp;Woo-Jung Song, MD, PhD ,&nbsp;You Sook Cho, MD, PhD ,&nbsp;Hyunkyoung Kim, MSc ,&nbsp;Jae-Woo Kwon, MD, PhD ,&nbsp;So-Young Park, MD, PhD ,&nbsp;Sujeong Kim, MD, PhD ,&nbsp;Gyu Young Hur, MD, PhD ,&nbsp;Byung Keun Kim, MD, PhD ,&nbsp;Young-Hee Nam, MD, PhD ,&nbsp;Min-Suk Yang, MD, PhD ,&nbsp;Mi-Yeong Kim, MD, PhD ,&nbsp;Sae-Hoon Kim, MD, PhD ,&nbsp;Byung-Jae Lee, MD, PhD ,&nbsp;Taehoon Lee, MD, PhD ,&nbsp;So Young Park, MD, PhD ,&nbsp;Min-Hye Kim, MD, PhD ,&nbsp;Young-Joo Cho, MD, PhD ,&nbsp;Tae-Bum Kim, MD, PhD","doi":"10.1016/j.waojou.2024.101000","DOIUrl":"10.1016/j.waojou.2024.101000","url":null,"abstract":"<div><h3>Background</h3><div>Limited understanding exists regarding the progression trajectory of severe eosinophilic asthma (SEA) patients on type 2 biologics therapies.</div></div><div><h3>Objective</h3><div>We aim to explore distinct longitudinal phenotypes of these patients based on crucial asthma biomarkers.</div></div><div><h3>Methods</h3><div>We enrolled 101 adult patients with SEA. Of these, 51 were treated with anti-IL5/IL5Rα or anti-IL5/IL5RαR antibody, and 50 with anti-IL-4Rα antibody. Multi-trajectory analysis, an extension of univariate group-based trajectory modeling, was used to categorize patients based on their trajectories of forced expiratory volume in 1 s (FEV₁), blood eosinophil counts (BEC), and fractional exhaled nitric oxide (FeNO) levels at baseline, and after 1, 6, and 12 months of treatment. Associations between trajectory-based clusters and clinical parameters were examined.</div></div><div><h3>Results</h3><div>Among anti-IL5/IL5Rα antibody-treated patients, 2 clusters were identified. The cluster characterized by higher baseline BEC and lower FEV₁ showed a better response, with improvements in FEV₁ and reductions in BEC over time. Among anti-IL-4Rα antibody-treated, 3 clusters were identified. Clusters with moderate BEC and FeNO at baseline demonstrated better improvements in FEV₁ and reductions in FeNO, despite increased BEC during follow-up. Conversely, individuals with extremely low FeNO and high BEC at baseline were more likely to experience poorer progression, demonstrating an increase in FeNO and a reduction in FEV₁.</div></div><div><h3>Conclusion</h3><div>To optimally monitor treatment response in SEA patients on type 2 biologics, integrating longitudinal biomarker features is essential.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 12","pages":"Article 101000"},"PeriodicalIF":3.9,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142699929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating clinical importance of sensitization to Ara h 6 quantitively in Japanese children","authors":"Sakura Sato MD ,&nbsp;Noriyuki Yanagida MD, PhD ,&nbsp;Ken-ichi Nagakura MD, PhD ,&nbsp;Kyohei Takahashi MD, PhD, MPH ,&nbsp;Magnus P. Borres MD, PhD ,&nbsp;Motohiro Ebisawa MD, PhD","doi":"10.1016/j.waojou.2024.101001","DOIUrl":"10.1016/j.waojou.2024.101001","url":null,"abstract":"<div><h3>Background</h3><div>The clinical importance of sensitization to <em>Arachis hypogaea</em> 6 (Ara h 6) in Japanese children remains unelucidated. We aimed to quantitatively evaluate the clinical importance of sensitization to Ara h 6 in managing peanut allergy in Japanese children.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed the data of children with or without symptoms induced by an oral food challenge or home dosing of up to 3 g of peanuts. The specific immunoglobulin E (sIgE) levels against peanuts, Ara h 2, and Ara h 6 were quantified using an ImmunoCAP assay.</div></div><div><h3>Results</h3><div>We examined 273 patients aged 4.6–9.8 years (median 6.3); 189 (69%) were male, 187 (68%) had allergies to peanuts, and 43 (16%) had anaphylactic reactions to peanuts. Ara h 6 and Ara h 2 co-sensitization was observed in 224 patients (82%). Ara h 6-sIgE levels were significantly associated with the probability of allergic reactions and anaphylaxis. The 95% probability of allergic reactions to peanuts was obtained at 44.5 kU_A/L of Ara h 6-sIgE, but the 95% probability of anaphylaxis could not be calculated. A combination of Ara h 6 and Ara h 2 could not improve diagnostic accuracy for allergic reactions and anaphylaxis to peanuts.</div></div><div><h3>Conclusion</h3><div>Sensitization to Ara h 6 played an important role in managing peanut allergy in Japanese children, and sIgE levels provided valuable predictive information for allergic reactions to peanuts. However, the measurement of Ara h 6 did not improve the diagnostic accuracy of anaphylaxis, and Ara h 2 alone might be sufficient for clinical evaluation in peanut allergy.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 12","pages":"Article 101001"},"PeriodicalIF":3.9,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142699935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A global survey addressing sustainability of pollen monitoring","authors":"Divya Dwarakanath BSc, MPhil ,&nbsp;Andelija Milic BSc, PhD ,&nbsp;Paul J. Beggs BSc, PhD ,&nbsp;Darren Wraith BCom, GradDipHE, BMath, PhD ,&nbsp;Janet M. Davies BSc, PhD","doi":"10.1016/j.waojou.2024.100997","DOIUrl":"10.1016/j.waojou.2024.100997","url":null,"abstract":"<div><h3>Background</h3><div>Contemporary airborne pollen records underpin environmental health warnings, yet how pollen monitoring networks are sustained is poorly understood. This study investigated by whom and how pollen monitoring sites across the globe are managed and funded.</div></div><div><h3>Methods</h3><div>Coordinators listed in the Worldwide Map of Pollen Monitoring Stations were invited to complete a digital questionnaire designed to survey the people and organisations involved, types, and duration of funding sources, as well as uses, purpose, and sharing of pollen information. Quantitative data were analysed by descriptive statistics and open text responses were examined by qualitative thematic analysis.</div></div><div><h3>Results</h3><div>Eighty-four of 241 (35%) coordinators from 37 countries responded. Universities (42%) and hospitals/health services (29%) were most commonly responsible for monitoring. Most sites involved employees (87%) in pollen monitoring, of whom many were part-time (41%) or casual (11%), as well as students (29%) and volunteers (6%). Pollen monitoring was additional to core duties for over one-third of sites (35%), and 25% reported pollen monitoring was an in-kind contribution. Whilst funding for pollen monitoring was often sourced from government agencies (33%), government research grants (24%), or non-government grants (8%), 92% reported more than 1 funding source, and 99% reported dependence on “partnerships or grants requiring co-contributions”, indicating a complex resourcing structure, of short duration (median 3 years). Common reasons why airborne pollen was monitored included clinical allergy, population environmental health, aerobiology and forecasting. Climate change, research, and social duty were also referenced.</div></div><div><h3>Conclusions</h3><div>Aerobiological monitoring is currently sustained by complex, insecure, and insufficient resourcing, as well as reliance on volunteerism. There are multiple direct, health-related, and other important uses of aerobiology data, that are aligned to multiple dimensions of sustainability. Evidence from this study can be used to inform the design of strategies to sustain the generation of aerobiology data.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 12","pages":"Article 100997"},"PeriodicalIF":3.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142699933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of guidelines for the management of atopic dermatitis in children","authors":"Maya Deva MBBS ,&nbsp;Merryn J. Netting PhD ,&nbsp;Jemma Weidinger MN, NP ,&nbsp;Roland Brand FACD ,&nbsp;Richard KS. Loh FRACP ,&nbsp;Sandra L. Vale PhD","doi":"10.1016/j.waojou.2024.100989","DOIUrl":"10.1016/j.waojou.2024.100989","url":null,"abstract":"<div><div>Atopic dermatitis (AD) is a chronic disease that is increasing in prevalence, particularly in children and people with skin of colour. Current management involves topical treatments, phototherapy and immunosuppressants, as well as newer therapies like dupilumab. Health professionals should also be aware of the specific management considerations for AD in people with skin of colour. This systematic review was conducted to examine global guidelines for the management of AD in children, compare management recommendations, examine specific recommendations for children with skin of colour, and assess the quality of the guidelines.</div><div>The databases Medline, Embase, CINAHL, Scopus, Guidelines International Network, and Emcare Nursing and Allied Health were searched to identify guidelines or articles relating to the management of AD in children from 1990 to 2023. A grey literature search was also undertaken. The recommendations from the guidelines were extracted and compared, and the quality of the guidelines was assessed using the Appraisal Guidelines for Research and Evaluation (AGREE) II tool.</div><div>A total of 1644 articles were identified from the initial search. Title and abstract screening, full text screening, and reference checking yielded 28 guidelines for the final appraisal and data extraction. The main variations in management recommendations were the timing of emollients, bleach baths, bath additives, oral antihistamines, and the age cut-offs for topical calcineurin inhibitors. Many guidelines were not updated to reflect newer therapies like dupilumab and topical phosphodiesterase-4 (PDE4) inhibitors. There were minimal recommendations regarding management of skin of colour. Only 12/28 guidelines met the satisfactory cut-off score for the AGREE II appraisal, largely due to a lack of well-documented methodology.</div><div>This review showed that the recommendations for AD management in skin of colour were consistently lacking. Despite generally consistent management strategies over the last 5 years, less than half of the guidelines met high-quality criteria, emphasising the importance of using tools like AGREE II in future guideline development.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 12","pages":"Article 100989"},"PeriodicalIF":3.9,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142662832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting allergen immunotherapy efficacy based on early maintenance phase response in routine clinical practice","authors":"Rundong Qin MD ,&nbsp;Wanyi Fu Ph.D ,&nbsp;Renbin Huang MD ,&nbsp;Mo Xian MD,&nbsp;Yubiao Guo MD,&nbsp;Li He MD,&nbsp;Xu Shi MD,&nbsp;Jing Li MD","doi":"10.1016/j.waojou.2024.100986","DOIUrl":"10.1016/j.waojou.2024.100986","url":null,"abstract":"<div><h3>Background</h3><div>While allergen-specific immunotherapy (AIT) is acknowledged as an effective treatment, its efficacy varies, and consensus on predictive indicators for AIT responders remains elusive.</div></div><div><h3>Objective</h3><div>This study aimed to identify alternative parameters for predicting AIT responders based on clinical data collected in daily practice.</div></div><div><h3>Method</h3><div>We conducted a retrospective analysis of patients with house-dust-mite-driven asthma and/or rhinitis who completed 3 years of subcutaneous AIT (3y-AIT). We assessed the efficacy of AIT using the estimated daily symptom and medication score (edSMS) during different treatment periods, including up-dosing, maintenance I, II, and III phases. These scores were derived from detailed records of symptoms and medication use for AIT injections. A responder was defined as an individual with a reduction in edSMS of at least 30% from up-dosing to maintenance III phase (ΔedSMS_U-M3).</div></div><div><h3>Results</h3><div>A cohort of 133 patients was analyzed, revealing a significant overall improvement in the disease condition after 3y-AIT. Responders demonstrated lower rates of polysensitization, daily tobacco smoke exposure, and milder pretreatment disease severity compared to non-responders (p = 0.003, p = 0.001, and p = 0.019, respectively). We observed 8 clinical response patterns among included subjects, but only a small group of patients (16/133, 12.03%) demonstrated consistent improvement throughout the 3y-AIT. Serum total immunoglobulin E (tIgE), specific immunoglobulin E (sIgE), sIgE/tIgE ratios, and edSMS during the up-dosing phase failed to differentiate the clinical response patterns or correlate with 3y-AIT efficacy. Notably, the reduction in edSMS from up-dosing phase to maintenance I phase (ΔedSMS_U-M1) significantly associated with the 3y-AIT outcome (r = 0.443, p &lt; 0.001). Receiver-operating characteristic curves indicated that ΔedSMS_U-M1, with a cut-off of 18.40%, effectively predicted responders (AUC: 0.75, sensitivity: 76.20%, specificity: 76.70%).</div></div><div><h3>Conclusion</h3><div>The individualized clinical responses to AIT may pose challenges in identifying predictors for treatment efficacy. Nonetheless, despite this complexity, our study highlights that the effectiveness observed in the early maintenance phase serves as a suitable predictor of 3y-AIT outcomes.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 12","pages":"Article 100986"},"PeriodicalIF":3.9,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142662831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmet needs in the management of hereditary angioedema from the perspective of Brazilian patients","authors":"Pedro Giavina-Bianchi MD, PhD ,&nbsp;Mara Giavina-Bianchi MD, PhD ,&nbsp;Raquel de Oliveira Martins ,&nbsp;Maria Cristina Fortunato PharmD ,&nbsp;Ana Claudia Guersoni MD, PhD","doi":"10.1016/j.waojou.2024.100992","DOIUrl":"10.1016/j.waojou.2024.100992","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent, potentially life-threatening angioedema episodes. Despite its severity, including the risk of asphyxiation, HAE often remains underdiagnosed. The disease significantly impacts patient quality of life (QoL), leading to anxiety, depression, and avoidance behaviors due to the unpredictable nature of attacks. Understanding the perspectives of patients is crucial for identifying unmet needs in managing this complex condition.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;This study aimed to gather real-world insights from Brazilian patients with C1 inhibitor deficiency HAE to identify their unmet needs and assess their perceptions of the effectiveness of current care in preventing and treating HAE attacks.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A cross-sectional study utilized a SurveyMonkey questionnaire distributed to HAE patients through ABRANGHE via email. Participants provided informed consent, and their responses were anonymous. The questionnaire, developed with input from experts and patients, covered aspects of HAE diagnosis, treatment experiences, and QoL assessments.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The survey included 178 HAE patients, predominantly female (81%), aged 30–50 years (58%), and college-educated (62%). The most common HAE defect was C1–INH deficiency (53%), followed by HAE-nC1INH (23%), with nearly a quarter unaware of their specific defect. Diagnosis delays were prevalent, with a significant number reporting 13–50 attacks annually (33%) and 15% experiencing more than 50 attacks per year. Laryngeal involvement was reported by 26% of respondents. Most patients (69%) attended regular follow-ups, with 72% on prophylactic treatment and 67% managing acute attacks. The most used acute treatment was Icatibant (49%), followed by pdC1INH (24%). However, confusion regarding medication use persisted, with 45% incorrectly believing that oral medications could effectively treat attacks. Key unmet needs identified included improved access to emergency rooms during attacks (73%), better availability of prophylactic treatment (69%), and enhanced access to specialized care (63%). Patients also emphasized the need for psychological support, increased awareness of HAE, and educational initiatives for patients and healthcare providers.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Discussion&lt;/h3&gt;&lt;div&gt;This study highlighted significant challenges in HAE management among Brazilian patients, particularly concerning delayed diagnosis, misconceptions about treatment, and inadequate access to specialized care and prophylactic treatments. The high frequency of emergency room visits underscores the difficulties in managing the disease. The substantial burden of HAE on QoL emphasizes the urgent need for improved physician education, streamlined diagnostic processes, and equitable access to effective medications and specialized care facilities&lt;strong&gt;.&lt;/strong&gt; Addressing these","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 11","pages":"Article 100992"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142654793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and trends of anaphylaxis among inpatients from 2003 to 2023 in Wuhan, China: A multicenter retrospective study","authors":"Le Li MD ,&nbsp;Nan Huang MD ,&nbsp;Wenjing Li MD ,&nbsp;Yaqi Yang MD ,&nbsp;Dongxia Ma MD ,&nbsp;Hao Chen MD, PhD ,&nbsp;Rongfei Zhu MD, PhD","doi":"10.1016/j.waojou.2024.100980","DOIUrl":"10.1016/j.waojou.2024.100980","url":null,"abstract":"<div><h3>Background</h3><div>The incidence of a disease can help health professionals to identify risk factors and health-care policymakers to develop corresponding policies. The realization of both purposes depends on comprehensive studies, especially studies done on a large scale. However, comprehensive studies on the incidence of anaphylaxis among inpatients in China are still notably scarce. Hence we aim to explore the incidence and clinical characteristics of anaphylaxis among inpatients over a span of 21 years in Wuhan, China.</div></div><div><h3>Methods</h3><div>We retrieved data on anaphylaxis cases from the Data Platform Application Portal (DPAP) across 3 medical centers of Tongji Hospital, Wuhan, China from January 1, 2003, to December 31, 2023.</div></div><div><h3>Results</h3><div>The data encompassed a total of 362 anaphylaxis patients from 2,139,272 inpatients. Among them 204 (56.4%) were male, and the median age was 45 years old. Over the past 2 decades, the incidence rate of anaphylaxis at Tongji Hospital was 16.92 per 100,000 individuals. After adjusting for gender and age, the annual standardized incidence rate was 234.53 per 100,000 individuals. The incidence rate of anaphylaxis among the inpatients revealed a relatively stable but slowly rising trend over the 21-year observation period. As for the triggers of anaphylaxis, drugs were responsible for 73.6% of triggers, with antibiotics representing the highest proportion of these cases (38.4%). Drug triggers also showed age-specific features: chemotherapy (17.9%) had the highest proportions among children aged 0–3 years; blood products were more prevalent in school-age children. 13.5% of the cases had an unknown cause. In anaphylaxis cases, despite that only 36.0% received epinephrine treatment, the application of epinephrine still showed an ascending trend. Moreover, the mortality rate for anaphylaxis was relatively low (1.6%), displaying a consistent downward trend.</div></div><div><h3>Conclusion</h3><div>Our study provides insights into the incidence of anaphylaxis among inpatients in Wuhan over a 21-year period. Drugs are the most common triggers for anaphylaxis, and the use of epinephrine in anaphylaxis management is far from optimal.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 11","pages":"Article 100980"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142555669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating serum periostin and YKL-40 as biomarkers for airway remodeling and hyperresponsiveness in pediatric asthma","authors":"Su Ji Kim MD ,&nbsp;Youn Joo Choi MD ,&nbsp;Man Yong Han MD, PhD ,&nbsp;Il Tae Hwang MD, PhD ,&nbsp;Hey-Sung Baek MD, PhD","doi":"10.1016/j.waojou.2024.100991","DOIUrl":"10.1016/j.waojou.2024.100991","url":null,"abstract":"<div><h3>Background</h3><div>Periostin and human chitinase-3-like protein 1 (YKL-40) have been suggested to be involved in the development of airway fibrosis and remodeling. This study aimed to investigate the relationship between serum periostin levels and airway hyperresponsiveness (AHR) and between serum YKL-40 levels and AHR in children with asthma, comparing periostin as a marker for Th2 inflammation and atopy with YKL-40.</div></div><div><h3>Methods</h3><div>The study involved children aged 6–15 years, comprising 75 with asthma and 29 healthy controls. We measured serum periostin and YKL-40 levels and performed exercise bronchial provocation tests, methacholine challenge tests, spirometry, and FeNO measurements.</div></div><div><h3>Results</h3><div>Compared to the healthy controls, asthmatic children exhibited significantly elevated levels of periostin (86.7 [71.0–104.0] vs 68.3 [56.0–82.0] ng/mL; P = 0.006) and YKL-40 (29.0 [15.0–39.5] vs 27.7 [14.0–34.1] ng/mL; P = 0.034). The subgroup analysis revealed that periostin levels were significantly higher in the atopic asthma group than in the healthy controls (P = 0.003), but not in the non-atopic asthma group. YKL-40 levels were elevated in both the atopic and non-atopic asthma groups compared to healthy controls (P = 0.012 and P = 0.001, respectively). Serum periostin levels were significantly correlated with the postexerceise maximum percentage decrease in forced expiratory volume (FEV₁), as well as with fractional exhaled nitric oxide (FeNO) and blood eosinophil counts, but showed no significant correlation with overall lung function. Conversely, serum YKL-40 levels were significantly linked to the Z score of FEV₁ and AHR to methacholine but not with AHR to exercise or FeNO or blood eosinophil count.</div></div><div><h3>Conclusions</h3><div>Periostin is linked to atopic asthma and correlates with exercise-induced bronchoconstriction, FeNO, and eosinophil counts, highlighting its role in Th2 inflammation. YKL-40 is a general asthma marker, indicating airway remodeling. These findings suggest that targeting these markers can improve personalized treatment strategies for pediatric asthma.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 11","pages":"Article 100991"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142555670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global change, climate change, and asthma in children: Direct and indirect effects - A WAO Pediatric Asthma Committee Report","authors":"Peter N. Le Souëf MD ,&nbsp;Yuichi Adachi MD, PhD ,&nbsp;Eleni Anastasiou MD ,&nbsp;Ignacio J. Ansotegui MD, PhD ,&nbsp;Héctor A. Badellino MD, PhD ,&nbsp;Tina Banzon MD ,&nbsp;Cesar Pozo Beltrán MD ,&nbsp;Gennaro D'Amato MD ,&nbsp;Zeinab A. El-Sayed MD, PhD ,&nbsp;Rene Maximiliano Gómez PhD ,&nbsp;Elham Hossny MD, PhD ,&nbsp;Ömer Kalayci MD ,&nbsp;Mário Morais-Almeida MD, PhD ,&nbsp;Antonio Nieto-Garcia MD, PhD ,&nbsp;David B. Peden MD, MS ,&nbsp;Wanda Phipatanakul MD ,&nbsp;Jiu-Yao Wang MD, DPhil ,&nbsp;I-Jen Wan MD, PhD ,&nbsp;Gary Wong MD ,&nbsp;Paraskevi Xepapadaki MD ,&nbsp;Nikolaos G. Papadopoulos MD, PhD","doi":"10.1016/j.waojou.2024.100988","DOIUrl":"10.1016/j.waojou.2024.100988","url":null,"abstract":"<div><div>The twenty-first century has seen a fundamental shift in disease epidemiology with anthropogenic environmental change emerging as the likely dominant factor affecting the distribution and severity of current and future human disease. This is especially true of allergic diseases and asthma with their intimate relationship with the natural environment. Climate change-related variables including increased ambient temperature, heat waves, extreme weather events, air pollution, and rainfall distribution, all can <strong>directly</strong> affect asthma in children, but each of these variables also <strong>indirectly</strong> affects asthma via alterations in pollen production and release, outdoor allergen exposure or the microbiome. Air pollution, with its many and varied respiratory consequences, is likely to have the greatest effect, as it has increased globally due to rapid increases in fossil fuel combustion, global population, crowding, and megacities, as well as forest burning and trees succumbing to an increasingly hostile environment. Human activities have also caused substantial deterioration of the global microbiome with reductions in biodiversity for molds, bacteria, and viruses. Reduced microbiome diversity has, in turn, been associated with increases in Th2 allergic responses and allergic disease. The collective effect of these changes has already shifted allergy and asthma disease patterns. Given that changes in climate have been relatively small to date, the unavoidable, much greater shifts in climate in the future are concerning. Determining the relative scale of the direct versus indirect effects of climate change variables is needed if effective avoidance and adaptive measures are to be implemented. This would also require much more basic, epidemiological, and clinical research to understand the causal mechanisms, the most relevant climate factors involved, the regions most affected and, most importantly, effective and actionable adaptation measures. We suggest that allergy and respiratory health workers should follow current guidance to reduce present risks related to climate change and watch for new recommendations to reduce future risks. Since the respiratory system is the one most affected by climate change, they also need to call for more research in this area and show strong leadership in advocating for urgent action to protect children by reducing or reversing factors that have led to our deteriorating climate.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 11","pages":"Article 100988"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142654794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Epidemiology of adult patients with atopic dermatitis in AWARE 1: A second international survey” [World Allergy Organ J 16 (3) (2023) 100724]","authors":"Jorge Maspero ,&nbsp;Norma De Paula Motta Rubini ,&nbsp;Jianzhong Zhang ,&nbsp;Gloria Sanclemente ,&nbsp;Julio Roberto Amador ,&nbsp;Marhira Hamdy El Sayed ,&nbsp;Alsan Chan Wai Ming ,&nbsp;Roni P. Dodiuk-Gad ,&nbsp;Issam Hamadah ,&nbsp;Suganthi Thevarajah ,&nbsp;Catalina Rincón-Perez ,&nbsp;Elena Fedenko ,&nbsp;Yik Weng Yew ,&nbsp;Mark B.Y. Tang ,&nbsp;Chia-Yu Chu ,&nbsp;Kanokvalai Kulthanan ,&nbsp;Ozlem Su Kucuk ,&nbsp;Anwar Al-Hammadi ,&nbsp;Lysel Brignoli ,&nbsp;Angelina Tsankova ,&nbsp;Laurent Eckert","doi":"10.1016/j.waojou.2024.100966","DOIUrl":"10.1016/j.waojou.2024.100966","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 11","pages":"Article 100966"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}